Genoptix

Genoptix is a leading clinical oncology laboratory specializing in hematology and solid tumors, and operates one of the largest hematopathology centers in the U.S. It provides personalized and comprehensive diagnostic services to hematologists, oncologists and pathologists, with a specialization in diagnosing cancers and disorders in bone marrow, blood and lymph nodes, as well as in solid tumor workups using molecular testing. Through an integrated approach to case management, Genoptix delivers individualized, actionable results for each patient to help the referring physician make the best treatment decision. www.genoptix.com.Explore more

Is this data correct?

Popular Searchesgenoptix IncGenoptixGenoptix Medical LaboratoryGeoptix Communications LLCGenoPlexSIC Code 80,807NAICS Code 62,621Show more

Is Genoptix your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Last 7 days

Product Launch: Get notified when Genoptix launches new products

Check out if Genoptix is spiking on competitors!

Congratulate Masked Content for being promoted to Masked Content at Genoptix

Funding: Get notified immidiatlly once Genoptix has new funding data

Competitive Alert! Recent activity has been detected by your competitor Masked Content

Genoptix, which may be a good buyer, showed buying intent in Masked Content Topic

Check if Genoptix has recently received funding, and reach out quickly before it becomes old news!

Website visits: Recent activity has been detected on your website

Click to see if Genoptix had a recent Job posting/layoffs

Earning: See what the market has to say on Genoptix recently announced quarterly report

Recommended Actions

Find VP level buyers at Genoptix

Find more new buyers

View Email Formats for Genoptix

Genoptix financials insights

Gather financial insights about Genoptix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.

2018

Other Financing Round

$28M

See All Genoptix's Financials Insights

Genoptix News & Media

Genoptix Launches FDA-Authorized BCR-ABL MRDx® TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna®(nilotinib)
CARLSBAD, Calif., Sept. 4, 2018 /PRNewswire/ -- Genoptix, Inc., a leading oncology diagnostic laboratory, announces the immediate availability of a proprietary, FDA-authorized BCR-ABL MRDx® TFR Monitoring Test for patients with chronic myeloid leukemia (CML) being treated with...
www.prnewswire.com
MolecularMD and Genoptix Enter into a Definitive Agreement to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna®
PORTLAND, Ore. and CARLSBAD, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation and Genoptix, Inc. announced today that they have entered into an exclusive agreement to market and perform diagnostic testing services and distribution of the MRDx® BCR-ABL Test. The MRDx® BCR-ABL Test
globenewswire.com
Genoptix Announces Termination of Merger Agreement with Rosetta Genomics and Now Focused on Next Steps
CARLSBAD, Calif., Feb. 26, 2018 /PRNewswire/ -- Genoptix, Inc., a leading oncology diagnostic laboratory announces that Rosetta Genomics ("Rosetta") was unable to secure the stockholder vote required to approve and consummate the acquisition, and consequently, the merger agreement has...
www.prnewswire.com
Genoptix to Acquire Rosetta Genomics for $10 Million in Cash
The value to Rosetta Genomics' equity holders is preliminarily estimated to be $0.60 per ordinary share, after deductions for debt, warrant termination payments, fees, expenses and other items CARLSBAD, CA / PHILADELPHIA, PA / REHOVOT, ISRAEL / ACCESSWIRE / December 15, 2017 / Genoptix, Inc., a leading oncology diagnostic laboratory, and Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to
www.accesswire.com
Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits
SAN DIEGO, Calif., Feb. 19, 2011 /PRNewswire via COMTEX/ --Genoptix, Inc. (Nasdaq: GXDX) announced today that it has entered into a memorandum of understanding ("MOU") providing for the settlement of the putative class action lawsuits currently pending in the Superior Court of the State of California, San Diego County (the "Court") - captioned (1) Page v. Genoptix, Inc., Case No. 37-2011-00050762-CU-BT-NC, (2) Schwitters v. Genoptix, Inc., Case No. 37-2011-00050783-CU-BT-NC and (3) The George Le
phx.corporate-ir.net

Frequently Asked Questions Regarding Genoptix

What is Genoptix's official website?

Genoptix's official website is www.genoptix.com

What is Genoptix's Revenue?

Genoptix's revenue is $64.1 Million

What is Genoptix's SIC code?

Genoptix's SIC: 80,807

What is Genoptix's NAICS code?

Genoptix's NAICS: 62,621

How many employees does Genoptix have?

Genoptix has 201-500 employees

What industry does Genoptix belong to?

Genoptix is in the industry of: Business Services, Healthcare Services, Research & Development

What companies has Genoptix acquired?

Genoptix has acquired the companies: Genoptix, HistoRx, SeqWright, Pathline

How do I contact Genoptix?

Genoptix contact info: Phone number: (760) 268-6200 Website: www.genoptix.com

What does Genoptix do?

What are Genoptix social media links?

Genoptix Linkedin page Genoptix Twitter page Genoptix Facebook page

Is Genoptix a public company?

Genoptix is private company therefore does not currently have an official ticker symbol

See more information about Genoptix

Genoptix

Overview

Headquarters

Phone Number

Website

Revenue

Industry

About Genoptix

Sell smarter with deeper company insights.

Is Genoptix your ideal customer?

Genoptix financials insights

Genoptix News & Media

Genoptix Launches FDA-Authorized BCR-ABL MRDx® TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna®(nilotinib)

MolecularMD and Genoptix Enter into a Definitive Agreement to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna®

Genoptix Announces Termination of Merger Agreement with Rosetta Genomics and Now Focused on Next Steps

Genoptix to Acquire Rosetta Genomics for $10 Million in Cash

Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits

Frequently Asked Questions Regarding Genoptix

Top Contacts
i

Get Started with ZoomInfo

Sign Up for Free

Supercharge Your Prospecting

Grow Your Business

Test Drive ZoomInfo's Directories